CVR 41953616Private limited company (ApS)Virksomhedsrådgivning og anden ledelsesrådgivning (702000)HolteFounded 14 Dec 2020
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about TJ Biotech Holding ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
1
CVR, 2021
Gross profit
70.4K
DKK, annual report 2025
-40.4% on 2024
Result
+4.2M
DKK, annual report 2025
Equity
18.6M
DKK, annual report 2025
Thomas Engelbrecht Nordkild Jonassen100% of capital and votes
Operating company
Dandex estimate: revenue or gross profit in the 2025 reportThomas Engelbrecht Nordkild Jonassensince 14 Dec 2020
Owners of 5% or more. CVR registers shares in bands, not exact figures.
100% of capital and votessince 14 Dec 2020
2 Danish companies.
CVR 4563944410% to under 15% of capital and votes
CVR 378524065% to under 10% of capital and votes
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 382382135% to under 10% of capital and votes21 Mar 2022 to 4 Jun 2025
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Dec 2021, monthly: 1 employee, 1 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FTE | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Dec 2021, published 17 Feb 2022.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit 70.4K, Operating profit 10.4K, Result for the year 4.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 23.9M, Equity 18.6M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 1,749 | 54 | 70 | 118 | 70 |
| Operating profit | +403 | -10 | 0 | +50 | +10 |
| Result for the year | +413 | -216 | -9,514 | +668 | +4,185 |
| Equity | 23,484 | 23,268 | 13,755 | 14,423 | 18,607 |
| Total assets | 24,509 | 23,731 | 18,140 | 18,947 | 23,928 |
| Employees (average) | 1 | 0 | 0 | 0 | 0 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | 23.5% | -96.9% | 30.7% | 68.9% | -40.4% |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | 0% | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 | Not reportednote 1 |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for TJ Biotech Holding ApS:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingNot read from the announcement | None | None | None | 40,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Demerger (spaltning), as the receiving company (modtagende selskab)
Source: CVR, read 18 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 18 Nov 2026.
2 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Revision:
Fratrådte:
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 07.09.2026.
Tiltrådte:
CVR-NR. 37543128 Cedra Godkendt Revisionsaktieselskab, Sønderbrogade 16, 8700 Horsens, den 07.09.2026.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående spaltning. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en spaltningsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende virksomheder må antages at være tilstrækkeligt sikrede efter spaltningen.
Virksomheden er d. 14.12.2020 opstået efter spaltning. Aktiver og gæld er overdraget fra CVR-nummer: 26415365 TJ BIOTECH HOLDING ApS, der samtidigt er opløst.
Seneste vedtægtsdato: 14.12.2020.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt ved spaltning kr. 40.000,00 til kurs 57.453,17, fuldt indbetalt.
Direktion:
Thomas Engelbrecht Nordkild Jonassen, den 14.12.2020.
Selskabet tegnes af en direktør eller af den samlede direktion.
Revision:
CVR-NR. 33963556 DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, Værkmestergade 2, 18., 8000 Aarhus C, den 14.12.2020.
Første regnskabsår:
01.01.2020 - 31.12.2020.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at eje kapitalandele i helt eller delvist ejede datterselskaber, investering og yde konsulentbistand inden for videnskabelige og bioteknologiske områder, samt hermed beslægtet virksomhed.
P-number 1026598091Pile Alle 20, 2840 Holte